Orforglipron is an investigational oral GLP-1 receptor agonist for treating type 2 diabetes (T2D) and obesity. Unlike injectable GLP-1 analogs (e.g., semaglutide), it offers convenient once-daily oral dosing.

Key information and effects:

Promotes significant weight reduction by suppressing appetite and slowing gastric emptying.

Enhances insulin secretion and reduces glucagon, improving glycemic control.

Eliminates injections, potentially improving adherence.

Disclaimer: This product is for laboratory research purposes only. Not for human or animal consumption. Cap colour subject to change.